Effects of sustained release bovine somatotropin (sometribove) on animal health in commercial dairy herds.

The health of dairy cows given bovine somatotropin (bST) for one lactation was evaluated in 28 commercial herds located in four regions of the United States. At least six herds were in a region and at least one herd/region contained fewer than 60 cows. Cows (n = 1213) were assigned randomly to control or bST groups and were treated beginning in wk 9 to 10 of lactation and every 14 d until dry-off or d 400 of lactation. Management was according to site practices. Cows were observed for health-related signs by farm personnel daily and by the herd veterinarian biweekly. Average 305-d test-day milk yields were 932 kg greater for bST-treated cows. Pregnancy rates, days open, twinning, cystic ovaries, or abortions were unaffected by treatments. Supplementation of cows with bST had no effect on total mastitis cases, total days of mastitis, duration of mastitis, or the odds ratio of a cow to develop mastitis. Cows supplemented with bST used more medications for health events other than mastitis. This usage was associated primarily with treatments for disorders of the foot and hock. Supplemented cows had a slight increase in foot disorders. There was no effect of supplementation with bST on culling from the herd or removal from study. Overall, the results confirm that label directions for bST are adequate for safe use under field conditions. All clinical signs observed in this study occur normally in dairy herds and were managed in cows supplemented with bST.

Recombinant bovine somatotropin (rbST) increases size and proportion of fast-glycolytic muscle fibers in semitendinosus muscle of creep-fed steers.

The objective of this study was to determine the effect of recombinant bovine somatotropin (rbST) on muscle fiber histology and histochemistry in creep-fed beef steers. Crossbred steer calves were assigned to one of two treatment groups: control (sham-injected; n = 12) or rbST-injected (0.09 mg x kg(-1) x d(-1); n = 12). Calves were injected every 14 d starting at d 28 of age until weaning at 205 d of age. Biopsies of the semitendinosus muscle were performed on d 100, and slaughter samples of semitendinosus muscle were collected for muscle fiber analyses on d 206. The rbST-treated calves had larger (P = 0.045) fast-twitch-glycolytic (FG) fibers [2,564 +/- 10 vs 2,351 +/- 11 microm2 cross-sectional area, respectively] than controls. No differences (P = 0.36) between rbST-treated and control steers in cross-sectional area were detected for slow-twitch-oxidative (SO) [1,192 +/- 20 vs 1,148 +/- 22 microm2, respectively] or fast-twitch-oxidative-glycolytic (FOG) fibers [1,484 +/- 35 vs 1,403 +/- 38 microm2, respectively]. The percentage distribution for FOG fibers was greater for control calves than for the rbST-treated calves (38.4 vs 34.9 +/- 0.1%, respectively; P = 0.014), whereas the percentage distribution for FG fibers was greater in the rbST-treated calves than for control calves (53.5 vs 48.4 +/- 0.2%, respectively; P = 0.03). The percentage distribution for SO fibers tended to be greater for the control calves than for the rbST-treated calves (13.1 vs 11.7 +/- 0.1%, respectively; P = 0.07). The percentage of FG fibers increased with age (45.4 vs 56.6 +/- 0.8%, respectively; P = 0.001), whereas the percentage distribution of SO (14.3 vs 10.5 +/- 0.5%, respectively) and FOG fibers (40.3 vs 32.9 +/- 0.7%, respectively) decreased (P = 0.001) from d 100 to d 206. The increased longissimus muscle area and dissectable lean tissue in rbST-treated calves are associated with a greater percentage of FG fibers, which possess larger cross-sectional areas than the other fibers.

The effects of long-term administration of recombinant bovine somatotropin (Posilac) and Synovex on performance, plasma hormone and amino acid concentration, and muscle and subcutaneous fat fatty acid composition in Holstein-Friesian bull calves.

The effect of recombinant somatotropin (rbST), Synovex (Syn), and their combination (rbST+Syn) on intact male calves was examined in an experiment that lasted an average of 238 d. Holstein-Friesian bull calves were allotted to one of four subtreatments (n = 14/treatment) in a factorial arrangement. There were two levels of rbST (0; rbST) and two levels of the estrogenic growth promoter Synovex (0; Syn). The rbST was administered once every 2 wk as injections of 500 mg of Posilac. Synovex (C and S) was implanted at 90-d intervals. The animals were fed for ad libitum consumption a diet with a metabolizable energy concentration of 11.7 MJ/kg DM and 15% crude protein. The hot carcasses were weighed after the removal of kidney, pelvic, and cod fats, which were weighed separately. The 12th rib cut was saved for analysis. Average daily gain and feed conversion efficiency were increased by rbST treatment by 9% (P < .005) and 10% (P < .016), respectively. There was no significant effect of Syn treatment, nor was there a rbST x Syn interaction. The proportion of the fat of the large depots in the carcass was reduced by 34% (P < .0001) and in the longissimus muscle by 32% (P < .16) owing to the rbST treatment. The plasma concentrations of GH, insulin, and thyroxin were increased by rbST treatment (P < .001, P < .01, and P < .03, respectively). The concentration of IGF-I was not affected. Synovex had no effect on plasma hormone concentration. Plasma essential and nonessential amino acid concentrations were reduced by 14 and 9%, respectively, when rbST was injected. Concentrations of cholesterol and fatty acids in muscle and subcutaneous fat were not affected (P > .072) by the rbST treatment. Synovex increased the monounsaturated fatty acids (MUFA), and the combinaton of Syn with rbST reduced polyunsaturated fatty acid (PUFA) concentration in the longissimus muscle (at the 12th rib). The reduced muscle fat content of the rbST-treated animals was associated with a trend toward an increase in polyunsaturated fatty acids.

Recombinant bovine somatotropin (rbST) administration to creep-fed beef calves increases muscle mass but does not affect satellite cell number or concentration of myosin light chain-1f mRNA.

Our objective in this study was to determine the effect of recombinant bovine somatotropin (rbST) on indices of muscle development in creep-fed beef calves. Crossbred steer calves were assigned to one of two treatment groups: control (sham-injected; n = 12) or rbST-treated (.09 mg x kg(-1) x d(-1); n = 12). Calves were injected every 14 d starting at d 28 of age and were weaned at 205 d of age. Supplemental creep feed was supplied free access to all calves to compensate for an expected increased protein and energy requirement in calves given rbST. Biopsy (d 100) and slaughter (d 206) samples of semitendinosus muscle were evaluated for satellite cell, myofiber nuclei numbers, and myosin light chain (MLC-1f) mRNA quantification. Myofiber nuclei and satellite cell numbers per 100 myofibers and MLC-1f mRNA:rRNA ratios at 100 and 206 d of age were not different (P > .10) between control and rbST-treated calves. Total gain, ADG, quality grade, femur length, percentage kidney, pelvic, and heart fat, dressing percentage, plasma IGF-I, and plasma urea nitrogen concentrations did not differ (P > .10) between control and rbST-treated calves. However, rbST-treated calves had larger longissimus muscle areas (P < .03), less marbling (P < .001), higher carcass conformation scores (P < .04), greater mass of separated muscle (P < .03), more ground meat (P < .01), and heavier carcass weights (P < .05) than control calves. Thus, rbST treatment increased muscle characteristics while nuclei number and MLC-1f mRNA concentrations remained the same, implying that the additional muscle growth was in a normal fashion.

Growth performance, endocrine, and metabolite responses of finishing hogs to porcine prolactin.

Prolactin, a member of the somatotropin-prolactin-placental lactogen gene family, increases feed intake and rate of weight gain in several species. To determine whether prolactin affects growth performance and carcass composition in swine, recombinant porcine prolactin (rpPRL) was administered to finishing hogs. Doses of 0, 2, 4, 8, and 16 mg of rpPRL/d and 4 mg of recombinant porcine somatotropin (rpST)/d were administered to groups of seven barrows and seven gilts initially weighing 75.0 +/- .2 kg for a 28-d period. Recombinant pPRL did not alter feed intake or growth rate or affect carcass composition. In addition, most growth-related blood variables did not change, although plasma IGF-I was increased in the 8 and 16 mg of rpPRL treatment groups. At slaughter, mammary development was apparent in rpPRL-treated gilts and was characterized by distended alveolar and ductal lumina and presence of secretory material. In rPST-treated hogs, feed intake was decreased 28% (P < .01), gain/feed was increased more in barrows than in gilts (59 vs 39%, treatment x sex interaction, P = .035), and growth rate was increased 22%, but in barrows only (treatment x sex interaction P = .005). Compared with those in control hogs, circulating concentrations of IGF-I, insulin, and glucose were 175, 311, and 22% higher, respectively, and of blood urea nitrogen were 62% lower in rpST-treated hogs (P < .05). These results suggest that rpPRL, at the doses administered, does not increase feed intake in finishing hogs in contrast to rats and other species.

Effect of bovine somatotropin administered to periparturient dairy cows on the incidence of metabolic disease.

Thirty-eight dry, pregnant Jersey cows were assigned to diet and bST treatment in a 2 x 2 factorial design. During the dry period, half of the cows were fed a normal TMR (0.4% Ca; 0.3 to 0.4% P), and half of the cows were fed a high Ca TMR (1.5 to 1.6% Ca; 0.4 to 0.7% P). The high Ca diets were designed to induce milk fever and were relatively cationic (194 to 293 meq/kg) compared with the normal diets (-131 to 30 meq/kg). A standard dairy diet was fed to all cows postcalving. Cows received subcutaneous injections of either an oil-based excipient or 500 mg of bST in an oil-based excipient every 14 d from 28 d before expected calving until approximately 14 d postcalving. Peripartal bST treatment decreased the incidence of clinical mastitis, did not affect incidence of milk fever, and increased the duration, but not the incidence, of ketosis in mature Jersey cows. Blood data confirmed the clinical responses and indicated that treated cows mobilized more bone Ca than did controls, as was evidenced by increased hydroxyproline concentrations. Treatment with bST did not affect blood concentrations of 1,25-dihydroxyvitamin D, Ca, or Mg. High Ca diets increased the incidence of milk fever and downer cow syndrome compared with normal diets. The effect of bST on mastitis and milk production must be considered as preliminary given the small size of the study. Although bST treatment increased Ca mobilization, the effect was insufficient to prevent milk fever in this model.

Nutrition during the dry period and hepatic lipid metabolism of periparturient dairy cows.

From dry-off until 7 d before expected parturition date, 30 Holstein cows were fed a low energy diet (control) to maintain body condition or high energy diets (high fat or isocaloric high grain) to attempt to increase body condition. After parturition, all cows were fed a common lactation diet. Body condition was unchanged for cows fed control or high grain diets, but was decreased for cows fed the high fat diet because DMI was decreased. Cows fed the high fat diet during the dry period had decreased triglyceride accumulation in the liver at 1 d postpartum, which was accompanied by lowered plasma NEFA, increased peroxisomal beta-oxidation of palmitate by liver homogenates, and decreased esterification of palmitate by liver slices. During the last 3 wk prepartum, cows fed the high fat diet had lower glycogen and higher acid-soluble carnitine in liver, higher concentrations of NEFA and bST in plasma, higher ratio of triiodothyronine to thyroxine in plasma, and lower concentrations of insulin and thyroxine in plasma than did cows fed the high grain diet. After parturition, cows fed the high fat diet during the dry period had decreased percentage and production of milk fat; differences among treatments were not significant for DMI, body condition, milk production, or milk protein. Periparturient lipid metabolism was altered significantly in cows fed a high fat diet during the dry period, although diet composition and nutrient intakes were confounded.

The effects of bovine somatotropin (bST) and porcine somatotropin (pST) on growth factor and metabolic variables in horses.

Effects of exogenous pST and bST on metabolic and growth factor variables were examined in three studies with lighthorse mares (455 to 545 kg). In Study 1, eight mares received five s.c. injections of bST or pST (30 mg/d). In Studies 2 and 3, five mares received one s.c. injection of a prolonged release formulation designed to deliver 500 mg of bST (Study 2) or pST (Study 3) over 14 d. Blood samples were collected for several days before injection to establish baseline values, at frequent intervals during treatment, and for several days thereafter. In all studies, blood urea nitrogen concentrations were decreased (P < .001) and insulin-like growth factor I (IGF-I) concentrations were increased (P < .001) within 48 h after bST or pST injection relative to pretreatment values. Similarly, insulin and glucose were increased (P < .001) relative to pretreatment values, after bST or pST administration. In Studies 2 and 3, circulating ST concentrations were increased (P < .001) for at least 14 d after injection, despite severe local tissue reactions at the prolonged release formulation injection site. Insulin-like growth factor I ligand blotting of serum revealed bands with molecular weights (MW) of 45, 32, 30, and 18 kDa, and two bands of > 96 kDa. These results indicate that 1) bST and pST are biologically active in horses, which respond metabolically to exogenous ST in a manner similar to other mammalian species, 2) circulating IGF binding proteins are present in horses, and 3) the commercially available dairy cow product POSILAC (Monsanto, St. Louis, MO) is not appropriate for the delivery of bST in horses due to injection site reactions accompanying the administration of the oil-based prolonged release formulation.

Effect of supplemental dietary fat or protein on the short-term milk production response to bovine somatotropin.

Effects of supplemental energy or protein on the milk production response to bST administration were examined in two separate trials. In trial 1, 40 cows were used in a 2 x 2 factorial, completely randomized design to determine the effects of bST and fat supplementation. The study consisted of a 7-d pretreatment period and a 42-d treatment period. Fat was top-dressed at 3.0 Mcal/d of NEL, and bST was administered. Supplemental fat had no effect on milk production, and NEL intakes were unaffected. Administration of bST increased milk production by 7.1 kg/d, and the milk production response was unaffected by supplemental fat. In trial 2, 4 cows were used in four periods with a 2 x 2 factorial arrangement in which water or casein was infused into the abomasum of cows fed for ad libitum intake or at 80% of their requirements. Diets and infusions were initiated simultaneously and continued for 11 d. All cows were given bST during the last 5 d. Infusion of water or casein did not alter the milk production response to bST, but restricted feeding reduced the bST response (3.2 vs. 7.2 kg/d). Concentrations of IGF-I in plasma were increased by bST administration, and the increase was greatest for cows fed for ad libitum intake. The milk production response to bST was not increased by additional energy or protein offered to cows fed well-balanced diets.

Comparative effectiveness of somatotropin and anabolic steroids in feedlot steers.

Crossbred steers (n = 252, BW = 379 +/- 28 kg) were allotted to 42 pens in a 2 x 3 factorial arrangement of treatments: control or steroid implant (STR; estradiol benzoate+progesterone [three lighter blocks reimplanted on d 84] and trenbolone acetate [reimplanted on d 63]), and either 0, 80, or 160 mg/wk of recombinant bovine somatotropin (bST). Steers were adapted to the finishing diet (12% roughage equivalent, 13% CP) before the start of the experiment and fed for 84 or 119 d. Blood samples were taken on d 0, 14, 28, 56, and 84 for plasma urea N (PUN), serum somatotropin (ST), plasma insulin-like growth factor I (IGF-I), and plasma amino acid assay. Few interactions were noted (P > .1). Gain was increased by both treatments: 1.30 vs 1.66 kg/d for control vs. STR (P < .001) and 1.44, 1.49, and 1.51 kg/d (linear, P = .07) for 0, 80, and 160 mg of bST/wk, respectively. Gain efficiency was also improved: 169 vs 205 g/kg (P < .001) and 177, 189, and 195 g/kg (linear, P < .001), respectively. Average PUN was decreased (P < .001) 29% by STR and decreased 17 and 29% by 80 and 160 mg of bST/wk, respectively (linear, P < .001). Somatotropin decreased mean serum ST compared with controls; STR increased ST 36% compared with controls. Average plasma IGF-I was increased (P < .001) 12% by STR and 13 and 19% (linear, P < .001) by 80 and 160 mg of bST/wk, respectively. Both STR and bST influenced (P < .05) plasma amino acid profiles. Indicators of carcass fatness were decreased linearly (P < .05) by bST; STR implant tended to decrease carcass fatness and increase longissimus muscle area, which was related to carcass weight. The anabolic effects of STR and bST were found to be additive and possibly independent in feedlot steers.

Performance, clinical chemistry, and carcass responses of finishing lambs to formulated sometribove (methionyl bovine somatotropin).

Formulated zinc methionyl bST (sometribove, 50, 100, or 150 mg) was administered as a single treatment once every 2 wk or as two equal treatments once/week to evaluate the efficacy of prolonged release delivery of bovine somatotropin (bST) in finishing lambs. Feed conversion during the 6-wk treatment period was improved 9 and 19% in lambs that received treatments once and twice/2 wk, respectively (P < .05), and the responses to differing doses were similar within a dosing frequency (P > .05). Carcass muscle:fat ratio indicators generally were affected in a dose-related manner and were independent of frequency of administration. For example, fat thickness was 17, 30, and 42% lower than control in lambs that received 50, 100, and 150 mg of formulated sometribove/2 wk, respectively (P < .05). Percentages of muscle were higher and of fat were lower with increasing dose of formulated sometribove, but weight of only fat was significantly affected (P < .05). Clinical chemistry indices of metabolic effects of bST (e.g., circulating bST, IGF-I, insulin, glucose, and urinary nitrogen concentrations) were affected in directions similar to those observed with bST administered by daily injection. The results of this study demonstrate the growth performance and carcass composition advantages of a formulation designed to deliver bST over a 2-wk period.

Effects of recombinant bovine somatotropin implants on serum concentrations of somatotropin, insulin-like growth factor-I and blood urea nitrogen in steers.

Four cross-bred beef steers averaging 346 kg were used in a 4 x 4 Latin square design to determine the effect of prolonged-release recombinant bovine somatotropin (rbGH) implants on serum concentrations of somatotropin (GH), insulin-like growth factor-I (IGF-I) and blood urea nitrogen (BUN). Recombinant bGH implants of 0, 40, 80 or 160 mg were administered subcutaneously in the tailhead during the 4 trial periods. Each steer received each treatment starting at 06:00 on day 0 with 21 days between treatments. Jugular vein blood samples were collected on days 0, 1, 2 and 3 (4 day time course for GH, IGF-I and BUN) and every 15 min (GH profile) for 6 h on day 3. Serum baseline GH values were higher (P < 0.10) for the 80 and 160 mg treatments than for the control, and peak amplitude was decreased (P < 0.05) by the 40 and 160 mg treatments. There was a trend (P < 0.11) for fewer GH peaks during the 160 mg treatment. Somatotropin concentrations decreased from day 1 to day 3 (P < 0.05) in a linear manner. Serum IGF-I concentrations increased (P < 0.05) in a linear dose-dependent manner from the 0 mg to the 160 mg treatment. BUN concentrations were not significantly altered by rbGH treatment. Results from this experiment indicate that rbGH implants significantly increase serum IGF-I and GH baseline concentrations while suppressing GH peak amplitude in finishing steers.

Stimulation of mammogenesis and lactogenesis by recombinant bovine placental lactogen in steroid-primed dairy heifers.

A model of induced lactation was modified to examine the effects of bovine prolactin (bPRL) and bovine placental lactogen (bPL) on mammary growth and differentiation. Thirty-two peripubertal, non-pregnant Holstein heifers were given daily s.c. injections of oestradiol (0.05 mg/kg) and progesterone (0.25 mg/kg) for 7 days to initiate mammary growth. Treatment with bromocriptine (40 mg/3 days) reduced serum PRL concentrations to approximately 25% of pretreatment levels, for the duration of the study. On the day following the last steroid injection, groups of eight heifers were given twice daily s.c. injections of either saline (negative control), recombinant bPRL (rbPRL; 80 mg/day) or recombinant bPL (rbPL; 80 and 160 mg/day) for 7 days. At the end of this period (day 15), growth and differentiation of the mammary glands were assessed. Treatment with rbPL increased total mammary DNA above control value by 50 and 60% for the 80 and 160 mg/day doses respectively. However, total DNA was not different for the control and rbPRL-treated groups. The blood serum concentration of alpha-lactalbumin was measured daily throughout the study and used as an index of mammary differentiation. Both rbPRL and rbPL stimulated mammary differentiation (i.e. induction of milk synthesis), although rbPRL appeared to be more potent than rbPL. These results indicate that rbPL is lactogenic in vivo and strongly suggest that bPL is a mammary mitogen.

Performance, clinical chemistry, and carcass responses of finishing lambs to recombinant bovine somatotropin and bovine placental lactogen.

Bovine placental lactogen (PL) is a partial somatotropin agonist in the cow and decreases urea nitrogen, indicating increased nitrogen retention. In the present study, the somatogenic effects of bovine PL (bPL; 4 and 8 mg/d) were compared with those of bovine somatotropin (bST; 4 and 8 mg/d) in finishing lambs. Measures of comparison included growth performance, carcass composition, and growth-related clinical chemistry traits. Although feed efficiency during the first 3 wk of treatment with bPL was improved by 14% (P < .05), feed efficiency for the full 6-wk treatment period did not differ from that of control lambs. Responsiveness to bPL may have been attenuated by high titer antibodies present after 2 wk of treatment. However, bPL also did not influence growth-related clinical chemistry traits during short-term (7 d) treatment, strongly suggesting that bPL was ineffective in finishing lambs at the doses tested. In contrast, bST improved 6-wk feed efficiency by an average of 17% (P < .05) and decreased feed intake by an average of 12% (P < .05). In addition, measures of carcass composition including longissimus muscle area, specific gravity of the rack, kidney and pelvic fat, and fat thickness demonstrated that bST, but not bPL, treatment decreased carcass fatness and increased carcass leanness. Treatment with bST, but not with bPL, affected IGF-I, insulin, glucose, and urea nitrogen in a dose-related manner. Thus, daily injections of bPL did not affect either performance or carcass quality, whereas performance and carcass responses of finishing lambs to bST were consistent with those reported by others.

Performance, carcass composition, and blood hormones and metabolites of finishing pigs treated with porcine somatotropin in hot and cold environments.

Two experiments were conducted to assess the ability for recombinant porcine somatotropin (rpST)-treated pigs to perform and cope with the demands of hot and cold environments. In the first experiment, finishing pigs were exposed to either a thermoneutral (TN; 18 to 21 degrees C) or a hot environment (H; 27 to 35 degrees C) for 35 d. In the second experiment, pigs were exposed to a TN or cold environment (C; 5 to 15 degrees C). The rpST delivered by a 6-wk prolonged-release system had no effect on ADG, whereas both H and C reduced ADG by 29.4 and 11.8%, respectively. In the first experiment, rpST-treated pigs consumed 17.6% less feed than control pigs, whereas rpST-treated pigs in H consumed 24.4% less feed than rpST-treated pigs in TN. Overall feed/gain ratios through the first 4 wk of both studies were improved by 21.8 and 14%, respectively, by rpST (P < .05) and were 24.3% poorer in C (P < .05) than in H. The changes in blood concentrations of pST, IGF-I, and IGF-II associated with rpST were not influenced by the different environments. Total body composition of rpST-treated pigs had increased amounts of protein (P < .05) and decreased amounts of fat (P < .05); H further reduced fat (P < .05). The C resulted in reduced protein content (P < .05). No evidence of thermal imbalance due to rpST was found as assessed by rectal temperature, respiration rate, and heat production estimated by indirect calorimetry and chemical analysis.

Comparison of performance, clinical chemistry, and carcass characteristics of finishing lambs treated with recombinant ovine or bovine somatotropins.

The variation in growth and carcass composition responses of lambs to somatotropin (ST) treatment may depend on the source of ST used as well as on other experimental conditions. In the present experiment, growth, carcass composition, and clinical chemistry responses to recombinantly produced ovine ST (oST) and two bovine ST (N-methionyl-bST[M-bST] and N-alanyl-bST[A-bST] were compared. Lambs weighing 42 kg were assigned to treatment groups of control (no injection) or 4 mg/d of M-bST, A-bST, or oST administered by s.c. injection for 6 wk. Growth rate was increased by an average of 30% and feed efficiency was improved by an average of 22% by ST treatment compared with control, and responses did not differ among ST. The IGF-I, insulin, and glucose concentrations were increased by 107, 700, and 53% compared with control, respectively, and did not differ among ST treatment groups. Urea nitrogen responses to A-bST and oST were transiently greater than those to M-bST. Although quality grade was not affected by treatment, an average .8-kg increase in weight of retail cuts was calculated from yield grade. Carcasses of ST-treated lambs were calculated to have 1.3 kg more muscle and 1.9 kg less fat. Although fat and muscle were affected more by oST than by M-bST on a percentage basis, they did not differ among treatment groups on a total weight basis. Thus, both bST variants and oST improved growth performance and carcass leanness. Decreased responses of some carcass variables to M-bST treatment may have been related to the presence of antibodies that were indicated by an increased number of positive responders in a relative bST binding assay.

Effects of decreased availability of glucose for dairy cows.

After a preliminary trial to establish dose responses to phlorizin, five Holstein cows at 6 wk postpartum were used to test the response of cows in negative energy balance to a sudden decrease in availability of glucose caused by phlorizin. Cows were fed equal amounts of feed twice daily to supply 100% of NRC recommendations for protein and 90% of NRC recommendations for NEL and were in negative energy balance throughout the experiment. Phlorizin at 0, 2, and 4 g/d was injected subcutaneously in equal amounts every 6 h for 48 h and caused excretion of 0, 225, and 337 g/d of glucose in urine. Milk production was not decreased, but percentage of milk fat increased linearly (3.34, 3.56, and 3.70%) with increasing phlorizin. Concentrations of glucose (64.2, 62.6, and 59.4 mg/dl) and insulin (518, 432, and 329 pg/ml) in blood plasma decreased linearly, whereas beta-hydroxybutyrate (6.11, 8.88, and 9.98 mg/dl) and NEFA (181, 220, and 271 mu eq/L) increased linearly. The changes were most dramatic during the final 12 h of the 48-h injection interval. Healthy, early lactation cows in negative energy balance seem to have the capacity to make metabolic adjustments to provide adequate substrates for maintenance and milk synthesis and to compensate for short-term increased needs for glucose.

Relationship of mode of porcine somatotropin administration and dietary fat to the growth performance and carcass characteristics of finishing pigs.

Ninety-six pigs were used to investigate the relationship of diet (control vs fat-supplemented with equal energy:protein ratios), porcine somatotropin (pST) administration (non-treated; 2 mg/d, daily injection; and 2 mg/d, 6-wk implant), and sex (barrows and gilts) to performance and carcass characteristics. Diet and pST treatments were initiated at 87 kg of BW and continued for 38 d. Both the fat-supplemented diet (P less than .001) and pST treatment (P less than .0001) improved feed efficiency. The effects of diet were accounted for by differences in energy density of the diets. Across diets, pST improved gain:feed ratio by 29 and 16% in pigs treated by daily injection and the implant, respectively; the two modes of delivery resulted in different responses (P less than .01). Circulating insulin-like growth factor I (IGF-I) levels, determined from blood samples drawn on d 35, were increased 2.5-fold above those of controls in pigs treated by either daily injection or the implant. However, the elevation of glucose and decrease in blood urea nitrogen concentrations in response to pST were of a greater magnitude in pigs treated by daily injection. Similarly, reductions in backfat thickness and the rate of backfat accretion determined by ultrasound were greater in response to the daily injection of pST than in response to the implant. Lean meat ratio, calculated from measurements with a Fat-O-Meater probe, was increased by 6 and 13% by the implant and daily injection, respectively. It is concluded that although the use of an implant that delivers pST on a continuous basis was as effective as the same dose administered as a bolus injection for increasing IGF-I levels, it was less effective in improving feed efficiency and carcass quality.

Insulin-like growth factors and binding proteins in ruminants and their nutritional regulation.

Insulin-like growth factors (IGF) are important mediators of growth, lactation, reproduction, and health. Considerable information on their role in ruminant animals has been learned in the past several years, but the precise mechanisms of their action are not known. The exact biological response of target cells is undoubtedly determined by the developmental state of the cell and synergism with other growth factors. Overall, somatomedins and their binding proteins seem to be major links between cellular developmental processes and nutrient supply. The mechanism by which nutrients control biological actions of somatomedins is not known but clearly involves the synthesis of IGF, as well as their binding proteins and receptors. In ruminants, severe feed restriction decreases circulating concentrations of IGF-I, whereas subtle alterations typical of those that occur in production systems have minimal effect. However, the responses of IGF to somatotropin are affected by modest alterations in nutritional status, including differences in nutritional status that are typically encountered in animal production systems.

Dose-response effects of recombinant bovine somatotropin implants on feedlot performance in steers.

One hundred twenty crossbred beef steers averaging 377 kg were used in a 2 x 4 factorial experiment to determine the dose-response effects of recombinant bovine somatotropin (rbST) implants on growth performance and carcass characteristics. The implant dosages were 0 (sham), 40, 80, or 160 mg/wk administered s.c. in the tailhead region on a weekly basis throughout the experiment. The steers were fed a high-concentrate diet, which contained either a degradable (DP; soybean meal) or an escape (EP; corn gluten and blood meal) protein source. No dietary protein effect or dietary protein x rbST level interactions were detected. Recombinant bST decreased both DMI (P less than .10) and feed/gain (P less than .05) in a linear dose-dependent manner. Dosage of rbST did not significantly affect (P greater than .10) ADG or final weight of the steers. Recombinant bST decreased backfat depth (P less than .10), marbling score (P less than .05), and quality grade (P less than .10) and increased yield grade (P less than .10) in a linear dose-dependent manner. Soft tissue composition of the 9-10-11th rib section was altered (P less than .01) by rbST administration in a linear dose-dependent manner. The percentage of protein in the rib section was increased by 9.4% and fat was decreased by 11.8% at the 160 mg/wk rbST level compared with the sham-implanted steers. Recombinant bST did not affect (P greater than .10) dressing percentage, hot carcass weight, kidney, pelvic, and heart fat, or longissimus muscle area.(ABSTRACT TRUNCATED AT 250 WORDS)